Yellow fever study

Prevention tool
A solution to the global vaccine shortage.
Quick access
The project

In brief

This project is completed and its funding by the MSF Foundation closed.

Status of the project

  • Problem analysis
  • Development
  • Evaluation
  • Deployment

The identified gap

Yellow fever is an acute viral haemorrhagic disease transmitted by infected mosquitoes. It is one of the most serious infectious disease threats in the world: according to the WHO, this disease kills more than 30,000 people each year, mainly in Africa. Because there is no treatment for this disease, vaccination remains the only solution to prevent it. However, it is a vaccine that takes a long time to produce and there are few manufacturers, so the ability to quickly increase production when needed is limited.

The MSF Foundation’s Response

The MSF Foundation finances a clinical trial led by Epicenter to prove the efficacy of dose fractionation of the yellow fever vaccine and in so doing, initiating large-scale change in practice in the event of an epidemic.



Les premiers résultats de l'étude sur la fièvre jaune publiés dans le Lancet

In detail

In July 2016, the demand for yellow fever vaccines exceeded the globally available doses. To save doses, WHO developed recommendations for the use of fractional doses of yellow fever vaccine.

Epicenter has conducted this study since 2017 in Kenya and Uganda. Its objective is to confirm that patients are as well immunized as with a full dose when injected with only 1/5th of the vaccine dose. The prospect would be a change in the WHO recommendation to authorize the use of fractional doses in the event of an epidemic so that the available doses cover the population at risk.

The study has 1630 participants cared for at Epicenter's research center in Mbarara, Uganda and the Kilifi Medical Research Institute in Kenya.

The first results of this research published in The Lancet on January 9, 2021, confirm that fractional doses of the vaccine offer the same protection as a full dose, even one year post vaccination. These results open up exceptional prospects in the fight against this disease which still kills many people today.



Who's involved?

Our partners

  • Epicentre Logo
  • Kenya Medical Research Institut logo
  • University Oxford logo

The Team

  • Aitana Juan Giner
    Aitana Juan Giner
    Epidemiologist - Study Coordinator

our other projects

  • ImageUneAntibiogoGde


    Antibiogo is a diagnostic aid medical device that aims to help doctors prescribe the most effective antibiotics to their patients. It is available as a free, open source and offline Android application. It allows non-expert laboratory technicians to measure and interpret antibiograms. It provides accurate results that can also be used for monitoring purposes and updating empirical treatments based on actual etiology.

  • UneAIforCC


    The MSF Foundation and its partners will conduct -upon ethical board validation of MSF and Malawian authorities- this clinical study in Malawi as part of MSF's program for care of women with cervical cancer at the Queen Elizabeth Hospital and the screening program in Blantyre health centers. 

  • ImageUne3D

    3D Programm

    The use of 3D technology makes it possible for the best experts to remotely design upper limb prostheses and compression orthoses using digital impressions of face and neck burns of patients treated by MSF in Jordan, Haiti, and Gaza.

  • UneAlerteEpidemie


    Alert-Epidemics is an alert processing and notification system to detect and respond to outbreaks of infectious diseases in precarious situations, including measles, meningitis, cholera and Covid19.

  • UneDiatropix

    RDTs : Measles and meningitis

    DiaTROPIX is a new platform for the development and production of rapid diagnostic tests (RDTs) at the Institut Pasteur in Dakar. This non-profit initiative aims to produce new rapid diagnostic tests that can be made available in countries where access to laboratory diagnosis is low or non-existent. 
    The MSF Foundation is financing and supporting the development by DiaTROPIX of two new RDTs for measles and meningitis. These two diseases with high epidemic potential represent a real public health problem in countries in which MSF conducts medical programmes, particularly in Sub-Saharan Africa. 

  • SmsAfyayetu


    A program designed to enable people living with a chronic disease, particularly those with medical or social vulnerabilities, to quickly identify and report problems that could lead to a lack of follow-up in their treatment or a deterioration of their state of health. 

  • UneEN_Reeduc

    Developing re-habiliation care

    Physiotherapy has been part of MSF activities for years, mostly regarding trauma and burns. The MSF Foundation launched in 2017 the 3D printing project and advance practice in rehabilitation for burn faces and upper limb prosthetics. In coordination with ops and medical team in MSF, the MSF Foundation will develop new activities and  support initiatives from the field to better integrate physiotherapy in our offer of care, especially regarding pediatrics, women health and burn rehabilitation.

  • Mini-Lab


    The purpose of the Mini-Lab project is to design and produce a small-scale, autonomous, transportable clinical bacteriology laboratory which is affordable and above all suited to the MSF’s fields of intervention. This concept, developed by MSF with its partners, is also intended to be made available to health care operators in countries with limited resources. The Mini-Lab project hosted by MSF has been able to benefit from other funding mechanisms and the Foundation has been able to redirect its funding to other emerging initiatives.